Incidental detection of small testicular tumors has increased in recent decades owing to the greater use of ultrasonography and cross-sectional imaging. For patients with low-risk prostate cancer or small renal masses, active surveillance represents a valid treatment option. Similarly, for men with small testicular masses <10 mm, active surveillance has been discussed as an alternative to surgery, although little is known regarding the behavior of small testicular germ cell tumors (GCTs). In the Swiss Austrian German Testicular Cancer Cohort Study we identified 849 patients (546 seminoma, 303 nonseminoma) treated with radical inguinal orchietomy for GCT with a median tumor diameter of 35 mm. A tumor diameter <10 mm was observed in 25 patients (13 seminoma, 12 nonseminoma). Of these, five patients (20%) presented with primary metastatic disease, all of whom had elevated tumor markers and nonseminomatous GCTs. Two patients (8%) with initially localized disease (1 seminoma, 1 nonseminoma) and without elevated tumor markers experienced relapse at 4 mo (nonseminoma) and 14 mo (seminoma) after orchietomy, despite the fact that the latter had received adjuvant chemotherapy. These findings highlight the metastatic potential of small testicular GCTs and raise the question of whether active surveillance for small testicular masses is safe.

Patient summary: This study on testicular cancer assesses the metastatic potential of small testicular germ cell tumors. Men with small testicular masses should be counseled about the malignant potential of small testicular germ cell tumors.

Incidental detection of urogenital tumors has increased in recent decades owing to the greater use of ultrasonography and cross-sectional imaging. For patients with low-risk prostate cancer or small renal masses, active surveillance represents a valid treatment option. Similarly, for men with small testicular masses <10 mm, active surveillance has been discussed as an alternative to surgery, although little is known regarding the behavior of small testicular germ cell tumors (GCTs). In the Swiss Austrian German Testicular Cancer Cohort Study we identified 849 patients (546 seminoma, 303 nonseminoma) treated with radical inguinal orchietomy for GCT with a median tumor diameter of 35 mm. A tumor diameter <10 mm was observed in 25 patients (13 seminoma, 12 nonseminoma). Of these, five patients (20%) presented with primary metastatic disease, all of whom had elevated tumor markers and nonseminomatous GCTs. Two patients (8%) with initially localized disease (1 seminoma, 1 nonseminoma) and without elevated tumor markers experienced relapse at 4 mo (nonseminoma) and 14 mo (seminoma) after orchietomy, despite the fact that the latter had received adjuvant chemotherapy. These findings highlight the metastatic potential of small testicular GCTs and raise the question of whether active surveillance for small testicular masses is safe.

Patient summary: This study on testicular cancer assesses the metastatic potential of small testicular germ cell tumors. Men with small testicular masses should be counseled about the malignant potential of small testicular germ cell tumors.

Incidental detection of urogenital tumors has increased in recent decades owing to the greater use of ultrasonography and cross-sectional imaging. For patients with low-risk prostate cancer or small renal masses, active surveillance represents a valid treatment option. Similarly, for men with small testicular masses <10 mm, active surveillance has been discussed as an alternative to surgery, although little is known regarding the behavior of small testicular germ cell tumors (GCTs). In the Swiss Austrian German Testicular Cancer Cohort Study we identified 849 patients (546 seminoma, 303 nonseminoma) treated with radical inguinal orchietomy for GCT with a median tumor diameter of 35 mm. A tumor diameter <10 mm was observed in 25 patients (13 seminoma, 12 nonseminoma). Of these, five patients (20%) presented with primary metastatic disease, all of whom had elevated tumor markers and nonseminomatous GCTs. Two patients (8%) with initially localized disease (1 seminoma, 1 nonseminoma) and without elevated tumor markers experienced relapse at 4 mo (nonseminoma) and 14 mo (seminoma) after orchietomy, despite the fact that the latter had received adjuvant chemotherapy. These findings highlight the metastatic potential of small testicular GCTs and raise the question of whether active surveillance for small testicular masses is safe.

Patient summary: This study on testicular cancer assesses the metastatic potential of small testicular germ cell tumors. Men with small testicular masses should be counseled about the malignant potential of small testicular germ cell tumors.
incidentally detected testicular masses are benign (e.g., epidermoid cysts, fibrothecoma, post-traumatic scar tissue) [1]. Assessment of tumor size or volume, fertility disorders, duration of symptoms, history of cryptorchidism, and testosterone levels can help in predicting the risk of malignancy [3].

It has been shown that in cases of uncertainty, tumor enucleation with intraoperative frozen-section examination (FSE) has high diagnostic accuracy in identifying malignant tumors [4]. To further eliminate the risk and burden of surgical interventions and reduce unnecessary orchietomies for benign testicular tumors, active surveillance has been discussed as an approach for small, incidentally detected testicular masses. An upper limit of 10 mm has been proposed as a cutoff for immediate surgical intervention [5,6], as the risk of malignancy increases with testicular mass size [7]. In order for active surveillance to be safe, the risk of metastasis needs to be low for small testicular masses. In contrast to low-risk prostate cancer [8] and small renal masses [9], little is known regarding the risk of metastatic disease or recurrence for small testicular GCTs. The aim of this study was to assess the risk of metastatic disease for men with testicular GCTs <10 mm.

The Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS) is a prospective, multinational cohort study enrolling curatively treated patients with GCTs in follow-up since December 2013 (NCT02229916). For all patients included, treatment is at the discretion of the local investigators in accordance with international guidelines for the treatment of GCT. The aim is to provide comprehensive long-term data regarding follow-up of patients with GCTs.

Patients treated with radical inguinal orchietomy and histologically verified testicular GCT were included in this analysis. Patients with extragonadal GCTs or contralateral GCTs were excluded from the analysis. A total of 849 patients with malignant testicular GCTs were enrolled between December 2013 and December 2021 and were included in this analysis. Of these, 546 (64%) had seminoma and 303 (36%) had nonseminoma. Regarding tumor stage, 465 patients (85%) with seminoma and 207 (68%) with nonseminoma presented with localized disease (stage I). Primary tumor size was determined on histological analysis and corresponded to the largest tumor diameter. The median tumor size for all patients included was 35 mm (range).

| Table 1 – Characteristics of patients with a testicular germ cell tumor <10 mm from the Swiss Austrian German Testicular Cancer Cohort Study |
|-----------------|-----------------|-----------------|
| Overall         | Seminoma        | Nonseminoma     |
|-----------------|-----------------|-----------------|
| Patients, n (%) | 25 (100)        | 13 (52)         |
| Median tumor diameter, mm (range) | 8 (3–9) | 7 (3–9) | 8 (5–9) |
| Clinical stage, n (%) |                |                |
| Stage I without adjuvant chemotherapy | 17 (68) | 12 (92) | 5 (43) |
| Stage I with adjuvant chemotherapy | 3 (12) | 1 (8) | 2 (16) |
| Stage >I (metastatic disease) | 5 (20) | 0 (0) | 5 (41) |
| Preoperative tumor markers, n (%) |     |     |
| Normal | 16 (64) | 11 (85) | 5 (41) |
| At least one elevated | 7 (28) | 0 (0) | 7 (59) |
| Missing | 2 (8) | 2 (15) | 0 (0) |
| Relapse of stage I, n (%) | 2 (10) | 1 (8) | 1 (14) |

*α-Fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase.

Two large retrospective studies assessed the rate of incidental testicular masses <10 mm detected on evaluation for male infertility. Bieniek et al. [10] identified a <10 mm incidental testicular mass in 120 out of 4088 men evaluated (3%). Surgery was performed in 18 of these patients during follow-up, with malignancy found in six cases, all of which were localized seminomas. Similarly, Toren et al. [5] detected a <10 mm incidental testicular mass in 46 of 4418 men (1%) evaluated for male infertility. Serial ultrasound follow-up was available for 38 men, with mean growth of 0.5 mm/yr noted. Eight of these men were ultimately treated surgically, with a localized seminoma detected in one patient [5]. In a cohort of 20 men with very small incidental testicular masses (<5 mm) and negative tumor markers who underwent surgical exploration and FSE, a malignant GCT was detected in four (20%) men [6]. Similarly, a retrospective analysis of men undergoing surgery for testicular masses demonstrated a higher rate of benign histology for small testicular masses, with half of the testicular tumors <10 mm being benign [7].

In this analysis, we assessed the metastatic potential of <10 mm testicular GCTs in the SAG TCCS. The rate of primary metastatic disease was similar for small testicular GCTs (20%) and the overall cohort (21%). All five patients (20%) presenting with primary metastatic small GCTs had marker-positive disease. Two further patients (10%) with initially marker-negative disease developed early relapse despite being treated with radical orchietomy and in one case even adjuvant chemotherapy. These findings highlight the metastatic potential of small testicular GCTs. Furthermore, our results show that initially negative results for tumor markers did not preclude the risk of early relapse for small testicular GCTs, even when detected and treated early. As this study exclusively assessed patients with histologically confirmed testicular GCTs, it does not assess the relative risk of malignant disease or metastasis for small testicular masses. Furthermore, the number of patients with small GCTs pose a limitation of this analysis.

Given the risk of progression in size and the metastatic potential of small GCTs, we recommend swift work-up for testicular masses. Surgical exploration with tumor
enucleation and histological examination via FSE is a reasonable approach in men with small testicular masses and negative tumor markers. If a malignant GCT is confirmed, radical orchiectomy remains the standard of care for men with bilateral testes.

Author contributions: Manolis Pratsinis had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: M. Pratsinis, Fankhauser, Rothermundt.
Acquisition of data: All authors.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: M. Pratsinis, K. Pratsinis.
Obtaining funding: Rothermundt, Gillessen.
Administrative, technical, or material support: All authors.
Supervision: Rothermundt.
Other: None.

Financial disclosures: Manolis Pratsinis certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding/Support and role of the sponsor: This study was supported by Alfred und Annelies Sutter-Stöttner Stiftung, Dr. Hans Altschüler Stiftung, Hanne Liebermann-Stiftung, Padella Stiftung, Stiftung zur Krebsbekämpfung, and Anna-Lisa Stiftung. The sponsors played no role in collection and management of the data.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.euros.2022.03.013.

References

[1] Carmignani L, Gadda F, Gazzano G, et al. High incidence of benign testicular neoplasms diagnosed by ultrasound. J Urol 2003;170:1783–6.
[2] Laguna M, Albers P, Algaba F, et al. EAU guidelines: testicular cancer. Arnhem, The Netherlands: European Association of Urology; 2021. https://uroweb.org/guidelines/testicular-cancer.
[3] Paffenholz P, Held L, Loosen SH, Pfister D, Heidenreich A. Testis sparing surgery for benign testicular masses: diagnostics and therapeutic approaches. J Urol 2018;200:353–60.
[4] Fankhauser CD, Roth I, Kranzbühler B, et al. The role of frozen section examination during inguinal exploration in men with inconclusive testicular tumors: a systematic review and meta-analysis. Eur Urol Focus 2021;7:1400–2.
[5] Toren PJ, Roberts M, Lecker I, Grober ED, Jarvi K, Lo KC. Small incidentally discovered testicular masses in infertile men—is active surveillance the new standard of care? J Urol 2010;183:1373–7.
[6] Müller T, Gozzi C, Akkad T, Pallwein L, Bartsch G, Steiner H. Management of incidental impalpable intratesticular masses of ≤5 mm in diameter. BJU Int 2006;98:1001–4.
[7] Shilo Y, Zisman A, Lindner A, et al. The predominance of benign histology in small testicular masses. Urol Oncol 2012;30:719–22.
[8] Dall’Era MA, Albertsen PC, Bangma C, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976–83.
[9] Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012;118:997–1006.
[10] Bieniek JM, Juvet T, Margolis M, Grober ED, Lo KC, Jarvi KA. Prevalence and management of incidental small testicular masses discovered on ultrasonographic evaluation of male infertility. J Urol 2018;199:481–6.

*Department of Urology, Canton Hospital St. Gallen, St. Gallen, Switzerland
**Department of Urology, Kantonsspital Luzern, Luzern, Switzerland
***Department of Medical Oncology, Inselspital University Hospital, University of Bern, Bern, Switzerland
****Department of Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland
*****Department of Urology, Canton Hospital Winterthur, Winterthur, Switzerland
******Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
*******Onkonzentrum Hirslanden, Klinik Hirslanden, Zurich, Switzerland
********Zentrum für Urologie und Nephrologie Bern, Bern, Switzerland
*********Department of Urology, University Medical Center Frankfurt, Frankfurt am Main, Germany
**********Department of Medical Oncology and Hematology, Kantonsspital Aarau, Switzerland
***********Onkologiezentrum, Kantonsspital Olten, Switzerland
************Medizinische Onkologie, Luzerner Kantonsspital, Luzern, Switzerland
*************Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany
**************Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Basel, Basel, Switzerland
***************Onkologie Kantonsspital Baselland, Liestal, Switzerland
***************Department of Oncology, St. Claraspital Basel, Basel, Switzerland
****************St. Clara Research and Faculty of Medicine, University of Basel, Basel, Switzerland
*****************Abteilung für Onkologie, Universität klinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria
*****************Ammerland-Klinik GmbH, Westerstede, Germany
****************†Medizinische Onkologie, Kantonsspital Frauenfeld, Frauenfeld, Switzerland
****************‡Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
****************§Università della Svizzera Italiana, Lugano, Switzerland
****************∥Department of Medical Oncology, Canton Hospital St. Gallen, St. Gallen, Switzerland
****************\ Corresponding author. Department of Urology, Cantonal Medical Center St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland. Tel: +41 71 4941416; Fax: +41 71 4942891. E-mail address: manolis.pratsinis@kssg.ch (M. Pratsinis).